Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
This is an open-label, phase I/II double arm study of the SV-BR-1-GM regimen in combination
with retifanlimab in patients with metastatic or locally recurrent breast cancer who have
failed standard therapy.
Patients will receive the SV-BR-1-GM regimen with combination immunotherapy. There will be an
initial evaluation of the combination of the SV-BR-1-GM regimen with retifanlimab every 3
weeks. If this is found to be safe and well tolerated in a cohort of at least 12 patients
(dose-limiting toxicities (DLTs) in less than 30% of the patients evaluated), then an
expansion cohort of up to 24 patients will be treated with that combination. These will be
randomized to two regimens differing in the timing of checkpoint inhibitor administration.
Phase
Phase 1/Phase 2
Funding Agency/Sponsor
Industrial
Disease
Breast Cancer
Enrollment Eligibility
Inclusion Criteria:
1. Have histological confirmation of breast cancer with recurrent and/or metastatic
lesions, as per the investigational site, and have failed prior therapy.
2. Patients with persistent disease and local recurrence must not be amenable to local
treatment.
3. For patients with metastatic disease:
1. Human epidermal growth factor 2 (HER2) positive and estrogen receptor (ER) or
progesterone receptor (PR) positive tumors: must be refractory to hormonal therapy
(e.g., aromatase inhibitor, tamoxifen or fluvestrant) and previously treated with at
least 2 regimens including at least two anti-HER2 agents (e.g., trastuzumab and
pertuzumab).
2. HER2 negative and either ER or PR positive tumors: must be refractory to hormonal
therapy (e.g. aromatase inhibitor, tamoxifen or fluvestrant) and previously treated
with at least 2 chemotherapy containing regimens.
3. HER2 positive and ER and PR negative tumors: must have failed at least 2 regimens
including at least two anti-HER2 agents (e.g., trastuzumab and pertuzumab).
4. Triple Negative tumors: Must have exhausted other available therapies including prior
treatment with a taxane and carboplatin.
Patients with new or progressive breast cancer metastatic to the brain will be eligible
provided:
a. The brain metastases must be clinically stable (without evidence of progressive disease
by imaging) for at least 4 weeks prior to first dose b. Must have received prior radiation
therapy for brain metastases or be ineligible for radiation therapy c. There is no need for
steroids and patients have not had steroids for at least 2 weeks d. No individual tumor
size is >50 mm e. Tumor is not impinging on Middle Cerebral Artery/speech-motor strip f. If
surgically debulked, must be healed from surgery and at least 3 weeks have elapsed since
general anesthesia g. Patients consent to MRI studies at 3-4 week intervals until evidence
of tumor regression on at least 2 imaging studies. In no case, will the interval between
MRI studies be longer than 3 months. MRI studies may be introduced at any time should the
patients develop new or clearly worsening symptoms and/or introduction of steroids
4. Be 18 years of age or older and female 5. Have expected survival of at least 4 months 6.
Have adequate performance status (ECOG 0-1) Patients with ECOG of 2 may be admitted only
with Sponsor approval.
7. Have provided written informed consent 8. For the Expansion cohorts, patients must also
either have:
1. Grade I (well-differentiated) or grade II (moderately differentiated) tumor histology
based on prior pathological findings OR
2. Match the SV-BR-1-GM cell line at least at one HLA type (HLA-A*24:02, B*35:08,
B*55:01, C*01:02, C*04:01, DRB3*01:01, DRB3*02:02, DRB1*11:04 or DRB1*13:03)
Exclusion Criteria:
1. Concurrent or recent chemotherapy, immunotherapy (except the SV-BR-1-GM regimen),
or general anesthesia/major surgery within 21 days. Patients must have recovered
from all known or expected toxicities from previous treatment and passed a
treatment-free "washout" period of 3 weeks before starting this program (8 weeks
for patients receiving nitrosourea or mitomycin). Prior immune related toxicity
should not have exceeded Grade 2 (with exception of endocrinopathy).
2. Radiotherapy within 14 days of first dose of study treatment with the following
caveats:
a. 28 days for pelvic radiotherapy. b. 8 weeks for brain metastases c. 6 months
for thoracic region radiotherapy that is > 30 Gy in 2 Gy fractions.
3. Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with
the exception of any grade of alopecia and anemia not requiring transfusion
support). Endocrinopathy, if well-managed, is not exclusionary and should be
discussed with medical monitor.
4. Participant has not recovered adequately from toxicities and/or complications
from surgical intervention before starting study drug.
5. History of clinical hypersensitivity to the designated combination immunotherapy,
GM-CSF, Interferon, yeast, beef, or to any components used in the preparation of
SV-BR-1-GM.
6. History of clinical hypersensitivity to any of the immunotherapies proposed for
combination treatment or their excipients.
7. Known hypersensitivity to another monoclonal antibody that cannot be controlled
with standard measures (e.g., antihistamines and corticosteroids) or known
allergy or hypersensitivity to any component of retifanlimab or formulation
components.
8. Serum creatinine OR Measured or calculated Creatinine Clearance (CrCl) (GFR can
also be used in place of creatinine or CrCl) >1.5 × ULN OR <30 mL/min for
participants with creatinine levels >1.5 × institutional ULN.
9. Absolute granulocyte count <1000; platelets <100,000; hemoglobin ≤ 9 g/L.
10. Bilirubin ≥ 1.5 × ULN unless conjugated bilirubin ≤ ULN; alkaline phosphatase >5x
upper limit of normal (ULN); ALT/AST >2x ULN. For patients with hepatic
metastases, ALT/AST >5x ULN is exclusionary.
11. INR or PT or aPTT > 1.5 × ULN, unless the participant is receiving anticoagulant
therapy as long as PT or aPTT is within therapeutic range of intended use of
anticoagulants. Note: See the restricted medications list in protocol section
5.9. If an alternative cannot be found, the participant cannot be enrolled.
12. Receiving any medication listed in the prohibited medication (section 5.10 of the
protocol).
13. Proteinuria >1+ on urinalysis or >1 gm/24hr.
14. History or presence of an abnormal electrocardiogram (ECG) that, in the
investigator's opinion, is clinically meaningful. Screening corrected QT interval
(QTc) interval >480 milliseconds is excluded (corrected by Fridericia or Bazett
formula). In the event that a single QTc is >480 milliseconds, the participant
may enroll if the average QTc for the 3 ECGs is <480 milliseconds.
16. Left ventricular ejection fraction (LVEF as determined by cardiac echo or MUGA
scan) below the normal limits of the institutions' specific testing range.
17. New York Heart Association stage 3 or 4 cardiac disease. 18. A pericardial
effusion of moderate severity or worse. 19. Symptomatic pleural effusion or ascites. A
participant who is clinically stable following treatment for these conditions
(including therapeutic thoraco- or paracentesis) is eligible.
20. Any woman of childbearing potential (i.e., has had a menstrual cycle within the
past year and has not been surgically sterilized), unless she: agrees to take
appropriate precautions to avoid becoming pregnant during the study (with at least 99%
certainty, see Appendix A for permitted methods) and has a negative serum pregnancy
test within 7 days prior to starting treatment.
21. Men must have been sterile or, if they were potentially fertile/reproductively
competent, should take appropriate precautions to avoid fathering a child for the
duration of the study.
22. Women who are pregnant or nursing. 23. Known additional malignancy that is
progressing or requires active treatment, or history of other malignancy within 3
years of study entry with the exception of cured basal cell or squamous cell carcinoma
of the skin, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma
in situ of the cervix, or other noninvasive or indolent malignancy, or cancers from
which the participant has been disease-free for > 1 year, after treatment with
curative intent.
24. Patients who are HIV positive (by self-report) or have clinical or laboratory
features indicative of AIDS.
25. Have a diagnosis of immunodeficiency or is receiving chronic systemic steroid
therapy (doses exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior to the first dose of study treatment.
25. Has had an allogeneic tissue/solid organ transplant. 26. Have an active autoimmune
disease that has required systemic treatment in past 2 years (i.e., with use of
disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement
therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy
for adrenal or pituitary insufficiency, etc.) is allowed.
27. Patients with a history of colitis. 28. Has a history of (non-infectious)
pneumonitis that required systemic steroids or current pneumonitis/interstitial lung
disease.
29. Known active HBA, HBV, or HCV infection, as defined by elevated transaminases with
the following serology: positivity for HAV IgM antibody, anti-HCV, anti-HBc IgG or
IgM, or HBsAg (in the absence of prior immunization).
30. Active infections requiring systemic therapy.
a. All antibiotic therapy within 28 days of initiating treatment must be recorded 31. Has a
known history of active tuberculosis (TB; Bacillus tuberculosis). 32. Patients with severe
psychiatric (e.g., schizophrenia, bipolar, or borderline personality disorder) or other
clinically progressive major medical problems, unless approved by the Investigator in
consultation with the medical monitor.
33. Has received a live vaccine within 28 days of the planned start of study drug. Note:
examples of live vaccines include, but are not limited to, the following: measles, mumps,
rubella, chicken pox/zoster, yellow fever, rabies, BCG, and typhoid vaccine. Seasonal
influenza vaccines for injection are generally killed virus vaccines and are allowed;
however, intranasal influenza vaccines (e.g., FluMist®) are live-attenuated vaccines and
are not allowed.
34. Patients may not be on a concurrent clinical trial, unless approved by the
Investigator.